Avelumab binds PD-L1 on target cells and, via its IgG1 Fc, engages FcγR-bearing effectors (e.g., NK cells) to mediate ADCC (and potentially ADCP), killing PD-L1–expressing cells; it also blocks PD-1/PD-L1 to restore CTL activity.